Education
About Us
Working with TipRanks
Follow Us
Satellos Bioscience (TSE:MSCL)
TSX:MSCL
Sat-3247
Muscular Dystrophies, Duchenne Muscular Dystrophy, Neuromuscular Diseases, Dmd, Duchenne
Phase II
Active Not Recruiting
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
Dec 11, 2025
―
Sat-3247
Duchenne Muscular Dystrophy
Early Phase I
Completed
First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort
Aug 19, 2024
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Satellos Bioscience (MSCL) have in its pipeline
MSCL is currently developing the following drugs: Sat-3247, Sat-3247, Sat-3247. These drug candidates are in various stages of clinical development as the company works toward FDA approval.